Achieve Life Sciences, Inc.
NASDAQ:ACHVBiotechnology
-$0.38 today
- Market cap
- $697.68M
- Beta
- 2.26
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.97
Volume 1.09M
Average 1.44M
ACHV Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Achieve Life Sciences, Inc.NASDAQ: ACHV
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$270.39M, compared with -$218.41M a year earlier.
Context
- Retained earnings amounted to 816.8% of total assets at the end of Q1 FY2026, up 18.5 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (260.23M) USD
- Year-over-year change
- -26.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (260.23M) | -26.6% |
| FY2024 | 2024-12-31 | (205.58M) | -24.0% |
| FY2023 | 2023-12-31 | (165.75M) | -21.9% |
| FY2022 | 2022-12-31 | (135.94M) | -45.3% |
| FY2021 | 2021-12-31 | (93.59M) | — |
Retained Earnings vs competitors
How ACHV compares with its peers on the latest reported figures
No competitor Retained Earnings figures are available to compare.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 43.02M | 24.72M | 15.55M | 12.73M | 20.93M |
| Short-term Investments | 0 | 0 | 0 | 21.61M | 15.48M |
| Net Receivables | 153K | 105K | 111K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.5M | 1.33M | 2.13M | 3.49M |
| Total Current Assets | 44.59M | 27.33M | 16.98M | 36.47M | 39.89M |
| Property, Plant & Equipment (Net) | 64K | 123K | 79K | 119K | 64K |
| Goodwill | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M |
| Intangible Assets | 1.64M | 1.42M | 1.2M | 974K | 751K |
| Long-term Investments | 0 | 0 | 50K | 0 | 20K |
| Tax Assets | 0 | 0 | 0 | 0 | 283K |
| Other Non-current Assets | 183K | 66K | 29K | 39K | (251K) |
| Total Non-current Assets | 2.92M | 2.64M | 2.39M | 2.17M | 1.9M |
| Total Assets | 47.52M | 29.97M | 19.37M | 38.63M | 41.79M |
| Account Payables | 841K | 1.66M | 618K | 1.95M | 867K |
| Short-term Debt | 0 | 16.07M | 16.66M | 0 | 3.77M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.94M | 1.68M | 2.84M | 3.03M | 2.53M |
| Total Current Liabilities | 4.55M | 21.6M | 20.81M | 6.68M | 9.08M |
| Long-term Debt | 14.92M | 0 | 0 | 9.84M | 11.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1.15M | 0 |
| Total Non-current Liabilities | 14.92M | 69K | 6K | 11.05M | 11.19M |
| Total Liabilities | 19.47M | 21.67M | 20.82M | 17.73M | 20.27M |
| Common Stock | 79K | 87K | 90K | 103K | 121K |
| Retained Earnings | (93.59M) | (135.94M) | (165.75M) | (205.58M) | (260.23M) |
| Accumulated OCI | 4K | 4K | 4K | 31K | 10K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 28.04M | 8.3M | (1.45M) | 20.9M | 21.52M |
| Total Debt | 14.99M | 16.2M | 16.73M | 9.96M | 14.96M |
| Net Debt | (28.03M) | (8.52M) | 1.19M | (2.78M) | (5.97M) |
Achieve Life Sciences, Inc.
NASDAQ:ACHV
Intrinsic Alpha fair value
Locked
Current Price
$6.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.